(elexacaftor + ivacaftor + tezacaftor) + ivacaftor

all catalysts(0)

nothing on the calendar yet

News(7)

• Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
  Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
  biopharma_dive · 1d ago
• Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
  A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.
  biospace · 1d ago
• STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
  A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.
  stat · 1d ago
• Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex
  Sionna Therapeutics has axed a cystic fibrosis add-on program after flunking a phase 2 trial, eliminating a would-be challenger to Vertex Pharmaceuticals’ empire. The biotech plans to “take actions…
  fiercebiotech · 2d ago
• Vertex’s biggest overhang: a rival 50 times smaller
  Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.
  biopharma_dive · 7d ago
• 10 clinical trials to watch in the second half of 2026
  The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
  biopharma_dive · 1mo ago
• Vertex earnings get muted investor response
  While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.
  biopharma_dive · 3mo ago